What is the AIDA Awards program?
The AIDA Awards program aims at providing scientists with AI-designed antibodies, or sequences, ready for biological assays, worth thousands of euros, entirely covered by MAbSilico.
The AIDA Awards program aims at providing scientists with AI-designed antibodies, or sequences, ready for biological assays, worth thousands of euros, entirely covered by MAbSilico.
The AIDA Awards 2022 is the first edition and celebrates the 5th anniversary of MAbSilico. During these years, MAbSilico has supported startup, biotech and biopharma companies in their drug discovery programs.
MAbSilico is revolutionizing the antibody drug discovery process by designing with AI antibodies that meet the criteria of efficacy, specificity, manufacturability and safety. We have analyzed more than 100 million antibody sequences, and selected batches of candidates on various targets, some of which are in preclinical and clinical development today.
The AIDA Awards is a unique opportunity for scientists from academia, biotech, and startups to collaborate with MAbSilico. Choose your target of interest and receive novel AI-designed novel antibodies!